Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MAR001 on Postprandial Lipids in Patients With Elevated Triglycerides and Remnant Cholesterol
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Willingness to provide informed consent and comply with the intervention and all study assessments
• Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period
• HbA1c ≥ 5.7% and ≤ 8.5%
• Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
• Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation
Locations
United States
California
Marea Site 301
RECRUITING
Chula Vista
Contact Information
Primary
Andrew Lane
MAR-104-info@mareatx.com
415-766-3610
Time Frame
Start Date: 2025-09
Estimated Completion Date: 2026-11
Participants
Target number of participants: 30
Treatments
Experimental: MAR001 Dose
Subcutaneous Injection
Placebo_comparator: Matching Placebo
Related Therapeutic Areas
Sponsors
Leads: Marea Therapeutics